unknown
Stage
About
BliNK Biomedical develops B cell–based antibody discovery technology to identify and isolate very rare antibody-secreting cells from humans and other species. Their validated platforms (ISAAC and VIVA|Screen) are used to discover and isolate therapeutic antibodies for difficult targets.
Explore BliNK Biomedical's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.